uniQure Announces Company Presentations at Upcoming October Conferences
October 02 2017 - 7:00AM
YASTEST
LEXINGTON, Mass. and AMSTERDAM,
the Netherlands, Oct. 02, 2017 (GLOBE NEWSWIRE) -- uniQure
N.V. (NASDAQ:QURE) a leading gene therapy company advancing
transformative therapies for patients with severe medical needs,
today announced company presentations at the following conferences
taking place in October:
Alliance for
Regenerative Medicine (ARM) 2017 Cell & Gene Meeting on the
Mesa, October 4 - 6 2017, at the Estancia La Jolla Hotel & Spa
in La Jolla, California.
- Jonathan Garen, chief business officer, will
present a corporate overview on Wednesday, October 4th, 2017 at
3:30 p.m. PDT. The live webcast can be accessed through the link
displayed in the Investor section of the uniQure website.
The webcast replay will be available for at least two weeks
following the live event.
European
Society of Gene & Cell Therapy (EGSCT) 25th Anniversary
Congress, October 17 - 20, 2017, at the BCC Berlin in Berlin,
Germany.
- Members of the uniQure research & development
team will be presenting new data focused on the progress and
optimization of uniQure's lead programs in gene therapy:
- Title: AAV5-miHTT gene
therapy demonstrates sustained huntingtin lowering and functional
improvement in Huntington disease mouse models
Session Title: 1b - Ocular and
Central Nervous System Gene and Cell Therapy I
Date and Time: Wednesday,
October 18th, 2017, from
8:30 - 10:40 am CET
- Title: Engineered AAV
capsids are successfully produced through the innovative approach
of combining directed evolution and the BEVS expression
system.
Poster and Date: P347 -
Wednesday, October 18th, 2017.
- Title: Development and
characterization of MFP-inducible GeneSwitch system for AAV5 gene
therapy of chronic diseases in the liver
Poster and Date: P160 -
Thursday, October 19th, 2017
4th Animal
Models of Neurodegenerative Disease Conference, October 22 - 24,
2017, at Chateau Liblice, Czech Republic.
- Members of the uniQure research & development
team will be presenting new data focused on progress in
technologies and development of animal models in gene therapy for
Huntington's disease:
- Title: Establishing
proof-of-concept of gene therapy for Huntington's
disease.
Date: Tuesday, October
24th, 2017,
morning session.
- Title: AAV-mediated
delivery in large animals.
Date: Monday, October
23rd, 2017,
afternoon session.
About
uniQure
uniQure is delivering on the promise of gene therapy - single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with hemophilia, Huntington's disease and cardiovascular
diseases. www.uniQure.com
uniQure
Contacts:
Maria E.
Cantor |
Eva M.
Mulder |
Tom
Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct:
339-970-7558 |
Mobile:
617-680-9452 |
Mobile: +31 6 52 33 15 79 |
Mobile:
339-223-8541 |
m.cantor@uniQure.com
|
e.mulder@uniQure.com
|
t.malone@uniQure.com |
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2024 to May 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From May 2023 to May 2024